Patent · US Active

Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof

US8575099B2 · kind B2 · utility

2Cited by
14References
15Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 30, 2007
Grant dateNov 5, 2013
Priority date
Expiry dateApr 25, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/4753
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention discloses an agent for treating a polyglutamine aggregation-caused disease or suppressing its onset, which comprises, as an active ingredient, (1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.